By Cancer Health –
Adoptive T cell therapies, in which a patient’s own immune cells are genetically engineered to target their cancer cells, have been remarkably effective in treating certain blood cancers. Unfortunately, this success has not translated to solid tumors, where T cells face unique challenges in the tumor environment that limit their persistence and function.
Recently, researchers have been turning to an unlikely source for answers, one infamously good at making genetic changes to overcome environmental obstacles. At Northwestern University, former Damon Runyon Clinical Investigator Jaehyuk Choi, MD, PhD, and his colleagues are modeling new T cell therapies after T cell cancers. The results, published in Nature, are promising.
